{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:49:01Z","timestamp":1791676141827,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":84,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T cell\u2013redirecting therapies directed against B-cell maturation antigen (BCMA) have revolutionized the treatment of relapsed or refractory multiple myeloma (MM). BCMA-directed CAR-T cell therapy has been reported to cause a parkinsonism-predominant neurotoxicity referred to as movement and neurocognitive toxicity (MNT). MNT is considered distinct from immune effector cell-associated neurotoxicity syndrome (ICANS) in terms of its clinical features and time to onset. However, MNT-like delayed-onset parkinsonism has not been well documented after BCMA-directed bispecific antibody (BsAb) therapy. We report the case of a woman with relapsed\/refractory MM who developed parkinsonism following elranatamab. She experienced neither cytokine release syndrome nor ICANS. Beginning the day after the Week 7 dose, she developed bradykinesia, repeated falls, gait disturbance, and cognitive decline. Neurological examination revealed hypomimia, bradykinesia, upper extremity rigidity, postural instability, and a shuffling gait, consistent with parkinsonism. Brain MRI and dopamine transporter single-photon emission computed tomography findings showed no findings suggestive of degenerative Parkinson\u2019s disease. Her symptoms gradually improved after discontinuation of elranatamab. This case highlights the possibility of delayed-onset parkinsonism with neurocognitive symptoms following treatment with a BCMA-directed BsAb. Clinicians should recognize the potential for delayed-onset parkinsonism and ensure close neurological monitoring in patients receiving these agents.<\/jats:p>","DOI":"10.1007\/s00277-026-07163-1","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:07:39Z","timestamp":1783393659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Delayed-onset parkinsonism possibly associated with elranatamab treatment for relapsed\/refractory multiple myeloma: a case report of a poorly characterized neurological event"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8693-6955","authenticated-orcid":false,"given":"Asuka","family":"Kono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1027-1552","authenticated-orcid":false,"given":"Yoshihiro","family":"Umezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2716-3377","authenticated-orcid":false,"given":"Keisuke","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8176-4760","authenticated-orcid":false,"given":"Takehiko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3142-8806","authenticated-orcid":false,"given":"Masahide","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"issue":"5","key":"7163_CR1","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.3390\/cancers15051558","volume":"15","author":"B Puertas","year":"2023","unstructured":"Puertas B, Gonz\u00e1lez-Calle V, Sobejano-Fuertes E et al (2023) Novel agents as main drivers for continued improvement in survival in multiple myeloma. Cancers (Basel) 15(5):1558","journal-title":"Cancers (Basel)"},{"key":"7163_CR2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41375-021-01471-3","volume":"36","author":"S Bal","year":"2022","unstructured":"Bal S, Malek E, Kansagra A et al (2022) Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. Leukemia 36:877\u2013880","journal-title":"Leukemia"},{"issue":"10297","key":"7163_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"24","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet Jul 24(10297):314\u2013324","journal-title":"Lancet Jul"},{"issue":"8","key":"7163_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"25","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr., Shah N et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med Feb 25(8):705\u2013716","journal-title":"N Engl J Med Feb"},{"issue":"9","key":"7163_CR5","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B et al (2023) Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 29(9):2259\u20132267","journal-title":"Nat Med"},{"key":"7163_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ et al (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387:495\u2013505","journal-title":"N Engl J Med"},{"key":"7163_CR7","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S et al (2024) Linvoseltamab for Treatment of Relapsed\/Refractory Multiple Myeloma. J Clin Oncol 42:2702\u20132712. https:\/\/doi.org\/10.1200\/JCO.24.01008","journal-title":"J Clin Oncol"},{"issue":"5","key":"7163_CR8","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/jcm14051451","volume":"14","author":"AG Buciuc","year":"2025","unstructured":"Buciuc AG, Tran S, Weber M et al (2025) Immune effector cell-associated neurotoxicity syndrome after CAR T-cell therapy and other psychiatric manifestations: a review and case series. J Clin Med 14(5):1451. https:\/\/doi.org\/10.3390\/jcm14051451","journal-title":"J Clin Med"},{"issue":"15","key":"7163_CR9","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129\u20132170","journal-title":"Mov Disord"},{"issue":"5\u20136","key":"7163_CR10","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000084558","volume":"19","author":"KW Kim","year":"2005","unstructured":"Kim KW, Lee DY, Jhoo JH et al (2005) Diagnostic accuracy of mini-mental status examination and revised hasegawa dementia scale for Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 19(5\u20136):324\u2013330","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"4","key":"7163_CR11","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","volume":"26","author":"CE Graham","year":"2025","unstructured":"Graham CE, Velasco R, Alarcon Tomas A et al (2025) Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee. Lancet Oncol 26(4):e203\u2013e213","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"7163_CR12","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1182\/blood-2024-201783","volume":"144","author":"AD Kumar","year":"2024","unstructured":"Kumar AD, Atallah-Yunes SA, Rajeeve S et al (2024) Delayed neurotoxicity after CAR-T in multiple myeloma: results from a global IMWG registry. Blood 144(Supplement 1):4758. https:\/\/doi.org\/10.1182\/blood-2024-201783","journal-title":"Blood"},{"issue":"7","key":"7163_CR13","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1002\/hem3.131","volume":"8","author":"A Couturier","year":"2024","unstructured":"Couturier A, Escoffre M, Leh F et al (2024) Parkinson-like neurotoxicity in female patients treated with idecabtagene-vicleucel. Hemasphere 8(7):e131. https:\/\/doi.org\/10.1002\/hem3.131","journal-title":"Hemasphere"},{"issue":"14","key":"7163_CR14","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood.2023020571","volume":"142","author":"P Karschnia","year":"2023","unstructured":"Karschnia P, Miller KC, Yee AJ et al (2023) Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood 142(14):1243\u20131248","journal-title":"Blood"},{"issue":"11","key":"7163_CR15","doi-asserted-by":"publisher","first-page":"e49192","DOI":"10.7759\/cureus.49192","volume":"15","author":"F Lutfi","year":"2023","unstructured":"Lutfi F, Abdallah AO, Nashatizadeh M et al (2023) Exploring the High-Grade and Refractory Neurotoxicity of Teclistamab: An Underreported Entity. Cureus 15(11):e49192. https:\/\/doi.org\/10.7759\/cureus.49192","journal-title":"Cureus"},{"issue":"1","key":"7163_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41408-025-01342-5","volume":"15","author":"M Janakiram","year":"2025","unstructured":"Janakiram M, Liu L, Goldsmith S et al (2025) GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series. Blood Cancer J 15(1):135. https:\/\/doi.org\/10.1038\/s41408-025-01342-5","journal-title":"Blood Cancer J"},{"key":"7163_CR17","unstructured":"Janssen Medical Connect TALVEY \u2013 Occurrence and Management of Ataxia and\/or Balance Disorders. https:\/\/www.jnjmedicalconnect.com\/products\/talvey\/medical-content\/talvey-occurrence-and-management-of-ataxia-andor-balance-disorders. Accessed 17 June 2026"},{"issue":"4","key":"7163_CR18","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","volume":"12","author":"A Chari","year":"2025","unstructured":"Chari A, Touzeau C, Schinke C et al (2025) Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study. Lancet Haematol 12(4):e269\u2013e281","journal-title":"Lancet Haematol"},{"issue":"5","key":"7163_CR19","doi-asserted-by":"publisher","first-page":"e631","DOI":"10.1016\/j.clml.2026.01.017","volume":"26","author":"O Tomkins","year":"2026","unstructured":"Tomkins O, Maamari RG, Douthwaite S et al (2026) Progressive Multifocal Leukoencephalopathy (PML) in 2 Patients Treated With Elranatamab. Clin Lymphoma Myeloma Leuk 26(5):e631\u2013e635. https:\/\/doi.org\/10.1016\/j.clml.2026.01.017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"7163_CR20","doi-asserted-by":"publisher","unstructured":"Le Henaff JR, Le Guennec L, Schiro P et al (2026) Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy. Blood Adv. bloodadvances.2026020556. https:\/\/doi.org\/10.1182\/bloodadvances.2026020556","DOI":"10.1182\/bloodadvances.2026020556"},{"key":"7163_CR21","unstructured":"Pharmaceuticals and Medical Devices Agency Japanese Adverse Drug Event Report database (JADER). https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/adr-info\/suspected-adr\/0003.html. Accessed 17 June 2026"},{"issue":"12","key":"7163_CR22","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen O, Aleman A, Upadhyaya B et al (2021) Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med 27(12):2099\u20132103","journal-title":"Nat Med"},{"issue":"12","key":"7163_CR23","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/mdc3.14239","volume":"11","author":"S Schneider","year":"2024","unstructured":"Schneider S, Aamodt WW, Pruitt AA, Berger JR (2024) Parkinsonism associated with anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy. Mov Disord Clin Pract 11(12):1625\u20131628","journal-title":"Mov Disord Clin Pract"},{"issue":"14","key":"7163_CR24","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1182\/bloodadvances.2024015721","volume":"9","author":"K Kelly","year":"2025","unstructured":"Kelly K, Cooperrider J, Bishop MR et al (2025) Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood Adv 9(14):3613\u20133616","journal-title":"Blood Adv"},{"issue":"2","key":"7163_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD et al (2022) Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J 12(2):32. https:\/\/doi.org\/10.1038\/s41408-022-00629-1","journal-title":"Blood Cancer J"},{"key":"7163_CR26","doi-asserted-by":"publisher","unstructured":"Uemura M, Marumo A, Obata A et al (2026) The effectiveness of elranatamab in the management of refractory multiple myeloma with central nervous system involvement. Intern Med 15. https:\/\/doi.org\/10.2169\/internalmedicine.6418-25","DOI":"10.2169\/internalmedicine.6418-25"},{"issue":"4","key":"7163_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/antib12040074","volume":"12","author":"R Ramapriyan","year":"2023","unstructured":"Ramapriyan R, Sun J, Curry A et al (2023) The role of antibody-based therapies in neuro-oncology. Antibodies (Basel) 12(4):74. https:\/\/doi.org\/10.3390\/antib12040074","journal-title":"Antibodies (Basel)"},{"key":"7163_CR28","doi-asserted-by":"publisher","first-page":"1276295","DOI":"10.3389\/fimmu.2023.1276295","volume":"14","author":"YG Mutlu","year":"2023","unstructured":"Mutlu YG, Y\u0131g\u0131t Kaya S et al (2023) Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case. Front Immunol 14:1276295. https:\/\/doi.org\/10.3389\/fimmu.2023.1276295","journal-title":"Front Immunol"},{"issue":"14","key":"7163_CR29","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood.2023021429","volume":"142","author":"CE Graham","year":"2023","unstructured":"Graham CE, Lee WH, Wiggin HR et al (2023) Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood 142(14):1248\u20131252","journal-title":"Blood"},{"issue":"1","key":"7163_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41408-025-01441-3","volume":"16","author":"KJC Lim","year":"2025","unstructured":"Lim KJC, Tan M, Parrondo R et al (2025) Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma. Blood Cancer J 16(1):18. https:\/\/doi.org\/10.1038\/s41408-025-01441-3","journal-title":"Blood Cancer J"},{"issue":"23","key":"7163_CR31","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1182\/blood.2024028172","volume":"145","author":"V Blumenberg","year":"2025","unstructured":"Blumenberg V, Puliafito BR, Graham CE et al (2025) Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment. Blood 145(23):2788\u20132793. https:\/\/doi.org\/10.1182\/blood.2024028172","journal-title":"Blood"},{"key":"7163_CR32","unstructured":"Food US, Administration D (2025) ELREXFIO (elranatamab-bcmm) injection, for subcutaneous use: prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761345s003lbl.pdf"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07163-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07163-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07163-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:07:02Z","timestamp":1791673622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07163-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["7163"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07163-1","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical review and approval were not required for this case report.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of this case report was obtained from the patient.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y. Umezawa has received honoraria from Daiichi Sankyo Co. and research funding from Janssen Pharmaceutical. M. Yamamoto has received honoraria from Janssen Pharmaceutical and Bristol-Myers Squibb. T. Mori has received honoraria from Daiichi Sankyo Co., Pfizer, Janssen Pharmaceutical and Bristol-Myers Squibb. The remaining authors have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"432"}}